Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: cyclerion.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2021 | $14.00 | Buy | Truist Securities |
| 9/24/2021 | $7.00 | Overweight | Cantor Fitzgerald |
SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
EFFECT - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
424B5 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
S-3 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
DEFA14A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Truist Securities initiated coverage of Cyclerion Therapeutics with a rating of Buy and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Cyclerion Therapeutics with a rating of Overweight and set a new price target of $7.00
Fastest customizable press release news feed in the world
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution. "These agreements demonstrate Cyclerion's progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets," said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. "These newly finalized agreements, combined with our significant redu
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion's operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited. "From the day Regina arrived at Cyclerio
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced the appointments of Dina Katabi,
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement. Tisento is launching with an $81 million Series A financing to support its development of the Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat in MELAS and other genetic mito
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. ("Cyclerion" or the "Company") (NASDAQ:CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards. On June 1, 2022, Cyclerion was notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the "Company", "Cyclerion Therapeutics", "Cyclerion") (NASDAQ:CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023. The reverse stock split was approved by the Company's stockholders at its annual meeting of stockholders held on May 15, 2023, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, each twenty shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued
Definitive agreement reached with new company ("NewCo") established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion Cyclerion CEO Peter Hecht Ph.D. to lead NewCo while continuing to serve on the Cyclerion board as one of the company's largest shareholders Biopharma executive Errol De Souza Ph.D. elected as chair of the Cyclerion board CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced corporate updates and first quarter 2023
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced today that it has signed a definitive agreement with a new private company ("NewCo") to sell two of its sGC stimulator assets in exchange for cash and equity ownership. Investors in NewCo have agreed to invest $81M to develop zagocig
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members (the "Independent Board"), has reviewed a non-binding proposal received on March 17, 2023 from an entity formed by investors that include the Company's Chief Executive Officer (CEO), to purchase the Company's zagociguat and CY3018 assets. After consultation with its legal and financial advisors, the Independent Board has concluded that the proposal merits further pursuit. Cyclerion has entered an exclusive negotiation arrangement for a limited period to allow the parties
Live Leadership Updates
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer's Disease with vascular pathology (ADv) enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update. "The data generated from our recent
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. "We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research program
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today the appointment of Errol De Souza, Ph.D., to its board of directors. Dr. De Souza is a seasoned R&D and business leader with broad experience - from large pharma to start ups - in the discovery and development of therapeutics for the treatment of central nervous system (CNS) disorders. Dr. De Souza is currently the executive chairman of Bionomics Limited and a member of the board of directors of Royalty Pharma and Catalyst Biosciences. Previously, Dr. De Souza founded
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer. A neurologist and neuroscientist, Dr. Wright brings to AavantiBio more than 20 years of medical research and drug development experience in specialty and CNS orphan diseases, including cystic fibrosis, dementias, epilepsy, mitochondrial diseases, and sickle cell disease. An accomplished scientific and medical leader in both the academic and biopharmaceutical communities, Dr. Wright most recently served as Senior Vice President and Chief Medical Off
ANDOVER, Mass., March 24, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021. Ms. Lovell brings over 30 years of healthcare executive management, legal and board experience in both the public and private sectors. Ms. Lovell is the Executive Vice President, Medicare and Chief Legal Officer for Blue Cross Blue Shield of Massachusetts, the largest private health pla
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics. “We are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and tr
This live feed shows all institutional transactions in real time.
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)